![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Alembic Pharmaceuticals Limited Vadodara In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Duloxetine hydrochloride, Process II, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2016-185 - Rev 00
This Chemical Type CEP, issued on December 13, 2021, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2594 associated with this CEP further emphasizes